

	<b>M21 - NITROGLYCERIN</b>	
	MEDICATION STANDING ORDER	
Version date: 2023-07-25	Effective date: 2023-09-19 (0700 hours)	

INDICATIONS
<ul style="list-style-type: none"> <li>• Chest pain or discomfort consistent with or suspicious for myocardial ischemia</li> <li>• Pulmonary edema</li> </ul>

CONTRAINDICATIONS
<ul style="list-style-type: none"> <li>• Hypotension (SBP less than 90 mmHg)</li> <li>• <u>Known</u> right ventricular infarct (RVI)</li> <li>• Use of any of the following within the last 24 hours <ul style="list-style-type: none"> <li>○ VIAGRA (sildenafil)</li> <li>○ CIALIS (tadalafil)</li> <li>○ LEVITRA (vardenafil)</li> </ul> </li> <li>• Increased intracranial pressure</li> <li>• Hypersensitivity to nitroglycerin</li> </ul>

ROUTE (WORK SCOPE)	INITIAL DOSE	REPEAT DOSE
SUBLINGUAL (PCP & ABOVE)	17 years & older - 0.4 mg	Every 5 minutes as required
TOPICAL / TRANSDERMAL (PCP & ABOVE)	17 years & older - 0.4 - 0.8 mg/hr	None

NOTES
<ol style="list-style-type: none"> <li>1. If the SBP drops more than 30 mmHg below the pre-administration (baseline) value, do not administer further sublingual doses (and remove topical nitroglycerin)</li> <li>2. <u>Use with caution</u> if any of the following is known or suspected: <ol style="list-style-type: none"> <li>a. Inferior myocardial infarction, with suspected right ventricular involvement</li> <li>b. Marked bradycardia (HR &lt; 50) or tachycardia (HR &gt; 120)</li> <li>c. Volume depletion</li> <li>d. Aortic or mitral stenosis</li> <li>e. Hypertrophic cardiomyopathy with LV outflow obstruction</li> </ol> </li> </ol>

f. Constrictive pericarditis or pericardial tamponade

**APPROVED BY**



Medical Director - Provincial EMS/PT



Associate Medical Director - Provincial EMS/PT

**VERSION CHANGES (refer to X08 for change tracking)**

- Revised administration table presents information for scope / route / dose more clearly